Trial Profile
A single centre, observational preliminary prospective study comparing on-treatment platelet reactivity and clinical outcome in prasugrel-treated and ticagrelor-treated T2D patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2018
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- 18 Oct 2018 New trial record
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes